Douglas Bootle

1.6k total citations · 1 hit paper
17 papers, 1.2k citations indexed

About

Douglas Bootle is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Douglas Bootle has authored 17 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 10 papers in Oncology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Douglas Bootle's work include PI3K/AKT/mTOR signaling in cancer (11 papers), Advanced Breast Cancer Therapies (7 papers) and Cancer Treatment and Pharmacology (6 papers). Douglas Bootle is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (11 papers), Advanced Breast Cancer Therapies (7 papers) and Cancer Treatment and Pharmacology (6 papers). Douglas Bootle collaborates with scholars based in Switzerland, United States and United Kingdom. Douglas Bootle's co-authors include Alistair Stewart, Prakash Mistry, Wendy Dangerfield, Peter Charlton, Cornelia Quadt, Dejan Juric, Chris Liddle, Howard A. Burris, Mark R. Middleton and Jane A. Plumb and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Douglas Bootle

17 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study

2018 302 citations Dejan Juric, Jordi Rodón et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Douglas Bootle Switzerland	13	718	582	304	171	150	17	1.2k
Franklin C. Harwood United States	16	919 1.3×	547 0.9×	168 0.6×	213 1.2×	144 1.0×	17	1.4k
Glen S. Germain United States	17	986 1.4×	558 1.0×	191 0.6×	165 1.0×	155 1.0×	30	1.6k
John K. Leighton United States	18	670 0.9×	463 0.8×	148 0.5×	270 1.6×	150 1.0×	34	1.6k
Aurora González‐Fierro Mexico	21	1.0k 1.4×	266 0.5×	127 0.4×	59 0.3×	233 1.6×	46	1.5k
Lucía Taja‐Chayeb Mexico	22	1.5k 2.1×	340 0.6×	165 0.5×	67 0.4×	358 2.4×	64	2.1k
Joanne Halsey United States	19	667 0.9×	1.1k 1.9×	298 1.0×	98 0.6×	145 1.0×	32	1.7k
HM Pinedo Netherlands	16	567 0.8×	691 1.2×	119 0.4×	63 0.4×	252 1.7×	20	1.3k
Sophie Callies United States	20	601 0.8×	321 0.6×	161 0.5×	142 0.8×	108 0.7×	44	1.2k
Ruoping Tang France	24	675 0.9×	729 1.3×	79 0.3×	386 2.3×	173 1.2×	40	1.7k
Karoline V. Gleixner Austria	29	848 1.2×	282 0.5×	232 0.8×	536 3.1×	86 0.6×	89	2.4k

Countries citing papers authored by Douglas Bootle

Since Specialization

Citations

This map shows the geographic impact of Douglas Bootle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas Bootle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas Bootle more than expected).

Fields of papers citing papers by Douglas Bootle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas Bootle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas Bootle. The network helps show where Douglas Bootle may publish in the future.

Co-authorship network of co-authors of Douglas Bootle

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas Bootle. A scholar is included among the top collaborators of Douglas Bootle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas Bootle. Douglas Bootle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Razak, Albiruni Ryan Abdul, Hung‐Ming Wang, Jang‐Yang Chang, et al.. (2023). A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Targeted Oncology. 18(6). 853–868. 10 indexed citations

Juric, Dejan, Jordi Rodón, Josep Tabernero, et al.. (2018). Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. Journal of Clinical Oncology. 36(13). 1291–1299. 302 indexed citations breakdown →

Juric, Dejan, Filip Jankú, Jordi Rodón, et al.. (2018). Alpelisib Plus Fulvestrant in PIK3CA -Altered and PIK3CA -Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer. JAMA Oncology. 5(2). e184475–e184475. 186 indexed citations

Jankú, Filip, Dejan Juric, Javier Cortés, et al.. (2015). Abstract PD5-5: Phase I study of the PI3Kα inhibitor BYL719 plus fulvestrant in patients with PIK3CA-altered and wild type ER+/HER2- locally advanced or metastatic breast cancer. Cancer Research. 75(9_Supplement). PD5–5. 12 indexed citations

Juric, Dejan, Martin Schüler, J. Schellens, et al.. (2014). Phase I Study of the Pi3K&Agr; Inhibitor Byl719, As a Single Agent in Patients with Advanced Solid Tumors (Ast). Annals of Oncology. 25. iv150–iv150. 7 indexed citations

Buck, Stefan S. De, Annamária Jakab, Markus Boehm, et al.. (2014). Population pharmacokinetics and pharmacodynamics ofBYL719, a phosphoinositide 3‐kinase antagonist, in adult patients with advanced solid malignancies. British Journal of Clinical Pharmacology. 78(3). 543–555. 25 indexed citations

Juric, Dejan, Martin Schüler, Jordan Berlin, et al.. (2013). Abstract P2-16-14: Preliminary safety, pharmacokinetics and anti-tumor activity of BYL719, an alpha-specific PI3K inhibitor in combination with fulvestrant: Results from a phase I study. Cancer Research. 73(24_Supplement). P2–16. 12 indexed citations

González-Angulo, Ana M., Dejan Juric, Guillem Argilés, et al.. (2013). Safety, pharmacokinetics, and preliminary activity of the α-specific PI3K inhibitor BYL719: Results from the first-in-human study.. Journal of Clinical Oncology. 31(15_suppl). 2531–2531. 43 indexed citations

Juric, Dejan, Jordi Rodón, Howard A. Burris, et al.. (2012). BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study. Cancer Research. 72. 29 indexed citations

10.

Juric, Dejan, Jordi Rodón, Ana M. González-Angulo, et al.. (2012). Abstract CT-01: BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study. Cancer Research. 72(8_Supplement). CT–1. 48 indexed citations

11.

Campone, M., Vincent Lévy, Emmanuelle Bourbouloux, et al.. (2009). Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours. British Journal of Cancer. 100(2). 315–321. 74 indexed citations

12.

Lerut, Evelyne, Tania Roskams, Douglas Bootle, et al.. (2005). Molecular pharmacodynamic (MPD) evaluation of dose and schedule of RAD001 (everolimus) in patients with operable prostate carcinoma (PC). Journal of Clinical Oncology. 23(16_suppl). 3071–3071. 17 indexed citations

13.

Zuylen, Lia van, John Bridgewater, Alex Sparreboom, et al.. (2004). Phase I and Pharmacokinetic Study of the Polyamine Synthesis Inhibitor SAM486A in Combination with 5-Fluorouracil/ Leucovorin in Metastatic Colorectal Cancer. Clinical Cancer Research. 10(6). 1949–1955. 16 indexed citations

14.

Campone, M., Vincent Lévy, Valérie Delecroix, et al.. (2004). 359 Phase Ib and pharmacokinetic studies of Everolimus (RAD001), a novel oral mTOR-inhibitor, with paclitaxel in patients with advanced solid tumors. European Journal of Cancer Supplements. 2(8). 108–108. 1 indexed citations

15.

Mistry, Prakash, Alistair Stewart, Wendy Dangerfield, et al.. (2002). In vitro and in vivo characterization of XR11576, a novel, orally active, dual inhibitor of topoisomerase I and II. Anti-Cancer Drugs. 13(1). 15–28. 50 indexed citations

16.

Stewart, Alistair, Prakash Mistry, Wendy Dangerfield, et al.. (2001). Antitumor activity of XR5944, a novel and potent topoisomerase poison. Anti-Cancer Drugs. 12(4). 359–367. 44 indexed citations

17.

Mistry, Prakash, Alistair Stewart, Wendy Dangerfield, et al.. (2001). In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.. PubMed. 61(2). 749–58. 302 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact